FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-0287							
l	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or	Section	on 30(n) d	of the	Investment C	ompany Ad	t of 1940							
1. Name and Address of Reporting Person* EBRIGHT GEORGE W						2. Issuer Name and Ticker or Trading Symbol NABI BIOPHARMACEUTICALS NABI							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
EDKIC	IIII GEC	JKGE W										1	X Director	or		10% Ov	vner	
(Last) (First) (Middle) C/O NABI BIOPHARMACEUTICALS					3. Date of Earliest Transaction (Month/Day/Year) 05/14/2004								Officer below)	(give title		Other (s below)	specify	
5800 PARK OF COMMERCE BLVD., N.W.						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)													•	iled by One	Repo	orting Perso	n	
BOCA R	RATON F	L	33487											iled by More	•	One Repor		
(City)	(5	State)	(Zip)															
		Tab	le I - Non-	-Deriva	ative	e Sec	curities	s Ac	quired, Di	sposed	of, or Be	neficial	ly Owned	l .				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)						ar) E	2A. Deemed Execution Date if any (Month/Day/Yea		, Transaction Disposed Code (Instr. 5)		rities Acqui ed Of (D) (In	red (A) or str. 3, 4 and	Benefici Owned I	es F ally (I Following (I	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code V	Amoun	(A) (D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration D (Month/Day/	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$16.65	05/14/2004			A		10,000		11/14/2004	05/14/2014	Common Stock	10,000	\$0	10,000)	D		

Explanation of Responses:

Remarks:

<u>/s/ Constantine Alexander, as attorney-in-fact</u>

05/18/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.